<DOC>
	<DOCNO>NCT00902330</DOCNO>
	<brief_summary>RATIONALE : Cranial microcurrent electrical stimulation ( CES ) mild electrical current receive electrode place earlobe . CES may lessen symptom woman breast cancer receive chemotherapy . It yet know whether CES effective sham therapy reduce symptom cause chemotherapy woman breast cancer . PURPOSE : This randomized phase III trial study mild electrical stimulation see well work compare sham therapy reduce symptom cause chemotherapy woman stage I , stage II , stage IIIA breast cancer receive chemotherapy .</brief_summary>
	<brief_title>Cranial Stimulation Chemotherapy Symptoms Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare effect cranial microcurrent electrical stimulation ( CES ) v sham CES time symptom depression , anxiety , fatigue , pain , sleep disturbance woman stage I-IIIA breast cancer receive adjuvant chemotherapy . Secondary - To explore relationship among select marker inflammation ( e.g. , tumor necrosis factor alpha , interleukin-6 , interleukin-1β , C-reactive protein ) , symptom , quality life . - To examine whether symptom depression , anxiety , fatigue , sleep disturbance , pain form cluster . - To examine effect CES quality life . OUTLINE : Patients stratify accord chemotherapy schedule ( every 2 week 8 course vs every 3 week 6 course ) . Patients randomize 1 2 treatment arm . - Arm I ( cranial microcurrent electrical stimulation [ CES ] ) : Patients receive CES unit ( Alpha-Stim® 100 Microcurrent Stimulator ) pass microcurrent level biphasic electrical stimulation via ear-lobe electrode . The CES unit preset provide 1 hour 100 μA ( sub-sensory level ) , modify square-wave biphasic stimulation 50 % duty cycle .05 Hz , automatically turn end 1 hour . Patients use CES unit daily week 1-18 . - Arm II ( sham CES ) : Patients receive CES unit arm I , ear-lobe electrode pass electrical current . Patients use CES unit daily week 1-18 . Patients complete symptom questionnaire ( e.g. , Hospital Anxiety Depression Scale , Brief Pain Inventory Short-Form , Brief Fatigue Inventory , General Sleep Disturbance Scale ) weekly week 1-18 . Patients also complete quality-of-life questionnaire week 1 , 7 , 18 . Blood sample collect week 1 , 7 , 18 analyze cytokine ( e.g. , tumor necrosis factor alpha , interleukin-6 , interleukin-1β ) C-reactive protein .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage IIIIA breast cancer Scheduled receive adjuvant chemotherapy Hormone receptor status specify PATIENT CHARACTERISTICS : Pre , peri , postmenopausal ECOG performance status 01 No dementia No active psychosis No history seizure disorder No implant electrical device PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy No initiation medication regimen depression psychiatric condition within past 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>depression</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>fatigue</keyword>
	<keyword>pain</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>